

# International Nonproprietary Names for Pharmaceutical Substances (INN)

---

## RECOMMENDED International Nonproprietary Names (Rec. INN): List 49

Notice is hereby given that, in accordance with paragraph 7 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances [*Off. Rec. Wld Health Org.*, 1955, **60**, 3 (Resolution EB15.R7); 1969, **173**, 10 (Resolution EB43.R9)], the following names are selected as Recommended International Nonproprietary Names. The inclusion of a name in the lists of Recommended International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or pharmacy.

Lists of Proposed (1–85) and Recommended (1–45) International Nonproprietary Names can be found in *Cumulative List No. 10, 2002* (available in CD-ROM only).

## Dénominations communes internationales des Substances pharmaceutiques (DCI)

### Dénominations communes internationales RECOMMANDÉES (DCI Rec): Liste 49

Il est notifié que, conformément aux dispositions du paragraphe 7 de la Procédure à suivre en vue du choix de Dénominations communes internationales recommandées pour les Substances pharmaceutiques [*Actes off. Org. mond. Santé*, 1955, **60**, 3 (résolution EB15.R7); 1969, **173**, 10 (résolution EB43.R9)] les dénominations ci-dessous sont choisies par l'Organisation mondiale de la Santé en tant que dénominations communes internationales recommandées. L'inclusion d'une dénomination dans les listes de DCI recommandées n'implique aucune recommandation en vue de l'utilisation de la substance correspondante en médecine ou en pharmacie.

On trouvera d'autres listes de Dénominations communes internationales proposées (1–85) et recommandées (1–45) dans la *Liste récapitulative No. 10, 2002* (disponible sur CD-ROM seulement).

## Denominaciones Comunes Internacionales para las Sustancias Farmacéuticas (DCI)

### Denominaciones Comunes Internacionales RECOMENDADAS (DCI Rec.): Lista 49

De conformidad con lo que dispone el párrafo 7 del Procedimiento de Selección de Denominaciones Comunes Internacionales Recomendadas para las Sustancias Farmacéuticas [*Act. Of. Mund. Salud*, 1955, **60**, 3 (Resolución EB15.R7); 1969, **173**, 10 (Resolución EB43.R9)], se comunica por el presente anuncio que las denominaciones que a continuación se expresan han sido seleccionadas como Denominaciones Comunes Internacionales Recomendadas. La inclusión de una denominación en las listas de las Denominaciones Comunes Recomendadas no supone recomendación alguna en favor del empleo de la sustancia respectiva en medicina o en farmacia.

Las listas de Denominaciones Comunes Internacionales Propuestas (1–85) y Recomendadas (1–45) se encuentran reunidas en *Cumulative List No. 10, 2002* (disponible sólo en CD-ROM).

**Latin, English, French, Spanish:**

*Recommended INN*    *Chemical name or description; Molecular formula; Graphic formula*

*DCI/Recommandée*    *Nom chimique ou description; Formule brute; Formule développée*

*DCI/Recomendada*    *Nombre químico o descripción; Fórmula empírica; Fórmula desarrollada*

**albaconazolum**

albaconazole

7-chloro-3-[(1*R*,2*R*)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1*H*-1,2,4-triazol-1-yl)propyl]quinazolin-4(3*H*)-one


albaconazole

7-chloro-3-[(1*R*,2*R*)-2-(2,4-difluorophényl)-2-hydroxy-1-méthyl-3-(1*H*-1,2,4-triazol-1-yl)propyl]quinazolin-4(3*H*)-one

albaconazol

7-cloro-3-[(1*R*,2*R*)-2-(2,4-difluorofenil)-2-hidroxi-1-metil-3-(1*H*-1,2,4-triazol-1-il)propil]quinazolin-4(3*H*)-ona

$C_{20}H_{16}ClF_2N_5O_2$



**alvimopanum**

alvimopan

[[[(2*S*)-2-[[[(3*R*,4*R*)-4-(3-hydroxyphenyl)-3,4-dimethylpiperidin-1-yl]methyl]-3-phenylpropanoyl]amino]acetic acid


alvimopan

acide [[[(2*S*)-2-[[[(3*R*,4*R*)-4-(3-hydroxyphényl)-3,4-diméthylpipéridin-1-yl]méthyl]-3-phénylpropanoyl]amino]acétique

alvimopán

ácido [[[(2*S*)-3-fenil-2-[[[(3*R*,4*R*)-4-(3-hidroxifenil)-3,4-dimetilpiperidin-1-il]metil]propanoil]amino]acético

$C_{25}H_{32}N_2O_4$





**apaziquonum**

apaziquone 5-(aziridin-1-yl)-3-(hydroxymethyl)-2-[(1*E*)-3-hydroxyprop-1-enyl]-1-methyl-1*H*-indole-4,7-dione

apaziquone 5-(aziridin-1-yl)-3-(hydroxyméthyl)-2-[(1*E*)-3-hydroxyprop-1-ényl]-1-méthyl-1*H*-indole-4,7-dione

apazicuona 5-(aziridin-1-il)-3-(hidroximetil)-2-[(1*E*)-3-hidroxiprop-1-enil]-1-metil-1*H*-indol-4,7-diona

**apolizumabum**

apolizumab immunoglobulin G1, anti-(human histocompatibility antigen HLA-DR) (human-mouse monoclonal Hu1D10  $\gamma$ 1-chain), disulfide with human-mouse monoclonal Hu1D10 light chain, dimer

apolizumab immunoglobuline G1, anti-(antigène d'histocompatibilité HLA-DR humain) (chaîne  $\gamma$ 1 de l'anticorps monoclonal de souris Hu1D10 humanisé), dimère du disulfure avec la chaîne légère de l'anticorps monoclonal de souris Hu1D10 humanisé



apolizumab inmunoglobulina G1, anti-(antígeno de histocompatibilidad HLA-DR humano) (cadena  $\gamma$ 1 del anticuerpo monoclonal humanizado de ratón Hu1D10), dímero del disulfuro con la cadena ligera del anticuerpo monoclonal humanizado de ratón Hu1D10

**asenapinum**

asenapine (3*aRS*,12*bRS*)-5-chloro-2-methyl-2,3,3*a*,12*b*-tetrahydro-1*H*-dibenzo[2,3:6,7]oxepino[4,5-*c*]pyrrole

asénapine (3*aRS*,12*bRS*)-5-chloro-2-méthyl-2,3,3*a*,12*b*-tétrahydro-1*H*-dibenzo[2,3:6,7]oxépino[4,5-*c*]pyrrole

asenapina (3*aRS*,12*bRS*)-5-cloro-2-metil-2,3,3*a*,12*b*-tetrahidro-1*H*-dibenzo[2,3:6,7]oxepino[4,5-*c*]pirrol

**axomadolum**

axomadol



(1*RS*,3*RS*,6*RS*)-6-[(dimethylamino)méthyl]-  
1-(3-methoxyphényl)cyclohexane-1,3-diol

axomadol

(1*RS*,3*RS*,6*RS*)-6-[(diméthylamino)méthyl]-  
1-(3-méthoxyphényl)cyclohexane-1,3-diol

axomadol

(1*RS*,3*RS*,6*RS*)-6-[(dimetilamino)metil]-  
1-(3-metoxifenil)ciclohexano-1,3-diol

**bifeprunoxum**

bifeprunox



7-[4-(biphenyl-3-ylmethyl)piperazin-1-yl]benzoxazol-2(3*H*)-one

biféprunox

7-[4-(biphényl-3-ylméthyl)pipérazin-1-yl]benzoxazol-2(3*H*)-one

bifeprunox

7-[4-(bifenil-3-ilmetil)piperazin-1-il]benzoxazol-2(3*H*)-ona



**canertinibum**


canertinib

*N*-[4-[(3-chloro-4-fluorophenyl)amino]-7-[3-(morpholin-4-yl)propoxy]quinazolin-6-yl]prop-2-enamide

canertinib

*N*-[4-[(3-chloro-4-fluorophényl)amino]-7-[3-(morpholin-4-yl)propoxy]quinazolin-6-yl]prop-2-énamide

canertinib

*N*-[4-[(3-cloro-4-fluorofenil)amino]-7-[3-(morfolin-4-il)propoxi]quinazolin-6-il]prop-2-enamida $C_{24}H_{25}ClFN_5O_3$ **cefovecinum**


cefovecin

(6*R*,7*R*)-7-[[[(2*Z*)-(2-aminothiazol-4-yl)(methoxyimino)acetyl]amino]-8-oxo-3-[(2*S*)-tetrahydrofuran-2-yl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid

céfovécine

acide (6*R*,7*R*)-7-[[[(2*Z*)-(2-aminothiazol-4-yl)(méthoxyimino)acétyl]amino]-8-oxo-3-[(2*S*)-tétrahydrofuran-2-yl]-5-thia-1-azabicyclo[4.2.0]oct-2-ène-2-carboxylique

cefovecina

ácido (6*R*,7*R*)-7-[[[(2*Z*)-(2-aminotiazol-4-il)(metoxiimino)acetil]amino]-8-oxo-3-[(2*S*)-tetrahidrofuran-2-il]-5-tia-1-azabicyclo[4.2.0]oct-2-eno-2-carboxílico $C_{17}H_{19}N_5O_5S_2$ 

**cethromycinum**

cethromycin


(3a*S*,4*R*,7*R*,9*R*,10*R*,11*R*,13*R*,15*R*,15a*R*)-4-ethyl-3a,7,9,11,13,15-hexamethyl-11-[[[3-(quinolin-3-yl)prop-2-enyl]oxy]-10-[[[3,4,6-trideoxy-3-(dimethylamino)-β-*D*-xylo-hexopyranosyl]oxy]octahydro-2*H*-oxacyclotetradecino[4,3-*d*]oxazole-2,6,8,14(1*H*,7*H*,9*H*)-tetrone

céthromycine

(3a*S*,4*R*,7*R*,9*R*,10*R*,11*R*,13*R*,15*R*,15a*R*)-4-éthyl-3a,7,9,11,13,15-hexaméthyl-11-[[[3-(quinoléin-3-yl)prop-2-ényl]oxy]-10-[[[3,4,6-tridésoxy-3-(diméthylamino)-β-*D*-xylo-hexopyranosyl]oxy]octahydro-2*H*-oxacyclotétradécino[4,3-*d*]oxazole-2,6,8,14(1*H*,7*H*,9*H*)-tétrone

cetromicina

(3a*S*,4*R*,7*R*,9*R*,10*R*,11*R*,13*R*,15*R*,15a*R*)-4-etil-3a,7,9,11,13,15-hexametil-11-[[[3-(quinolein-3-il)prop-2-enil]oxi]-10-[[[3,4,6-tridesoxi-3-(dimetilamino)-β-*D*-xilo-hexopiranosil]oxi]octahidro-2*H*-oxaciclótetradecino[4,3-*d*]oxazol-2,6,8,14(1*H*,7*H*,9*H*)-tetrona

C<sub>42</sub>H<sub>59</sub>N<sub>3</sub>O<sub>10</sub>**dabigatranum etexilatum**

dabigatran etexilate


ethyl 3-[[[2-[[[4-[[[(hexyloxy)carbonyl]amino]iminomethyl]phenyl]amino]=methyl]-1-methyl-1*H*-benzimidazol-5-yl]carbonyl](pyridin-2-yl)amino]propanoate

dabigatran étexilate

3-[[[2-[[[4-[[[(hexyloxy)carbonyl]amino]iminométhyl]phényl]amino]méthyl]-1-méthyl-1*H*-benzimidazol-5-yl]carbonyl](pyridin-2-yl)amino]propanoate d'éthyle

dabigatrán etexilato

3-[[[2-[[[4-[[[(hexiloxi)carbonil]amino]iminometil]fenil]amino]metil]-1-metil-1*H*-bencimidazol-5-il]carbonil](piridin-2-il)amino]propanoato de etilo

C<sub>34</sub>H<sub>41</sub>N<sub>7</sub>O<sub>5</sub>

**ecromeximabum**

ecromeximab

immunoglobulin G1, anti-(GD3 ganglioside) (human-mouse monoclonal KM871  $\gamma$ 1-chain), disulfide with human-mouse monoclonal KM871  $\kappa$ -chain, dimer

écromeximab

immunoglobuline G1, anti-(ganglioside GD3) (chaîne  $\gamma$ 1 de l'anticorps monoclonal chimérique homme-souris KM871), dimère du disulfure avec la chaîne  $\kappa$  de l'anticorps monoclonal chimérique homme-souris KM871

ecromeximab

inmunoglobulina G1, anti-(gangliósido GD3) (cadena  $\gamma$ 1 del anticuerpo monoclonal quimérico hombre-atón KM871), dímero del disulfuro con la cadena  $\kappa$  del anticuerpo monoclonal quimérico hombre-ratón KM871

**eculizumabum**

eculizumab

immunoglobulin, anti-(human complement C5  $\alpha$ -chain) (human-mouse monoclonal 5G1.1 heavy chain), disulfide with human-mouse monoclonal 5G1.1 light chain, dimer

éculizumab

immunoglobuline, anti-(chaîne  $\alpha$  du complément C5 humain) (chaîne lourde de l'anticorps monoclonal de souris 5G1.1 humanisé), dimère du disulfure avec la chaîne légère de l'anticorps monoclonal de souris 5G1.1 humanisé

eculizumab

inmunoglobulina, anti-(cadena  $\alpha$  del complemento C5 humano) (cadena pesada del anticuerpo monoclonal humanizado de ratón 5G1.1), dímero del disulfuro con la cadena ligera del anticuerpo monoclonal humanizado de ratón 5G1.1

**elzasonanum**

elzasonan


(2Z)-4-(3,4-dichlorophenyl)-2-[2-(4-methylpiperazin-1-yl)benzylidene]thiomorpholin-3-one

elzasonan

(2Z)-4-(3,4-dichlorophényl)-2-[2-(4-méthylpipérazin-1-yl)benzylidène]thiomorpholin-3-one

elzasonán

(2Z)-4-(3,4-diclorofenil)-2-[2-(4-metilpiperazin-1-il)bencilideno]tiomorfolin-3-ona

 $C_{22}H_{23}Cl_2N_3OS$ 


**enecadinum**

enecadin


4-(4-fluorophenyl)-2-methyl-6-[[5-(piperidin-1-yl)pentyl]oxy]pyrimidine

énécadine

4-(4-fluorophényl)-2-méthyl-6-[[5-(pipéridin-1-yl)pentyl]oxy]pyrimidine

enecadina

4-(4-fluorofenil)-2-metil-6-[[5-(piperidin-1-il)pentil]oxi]pirimidina

 $C_{21}H_{28}FN_3O$ **ertiprotafibum**


ertiprotafib

(2*R*)-2-[4-(9-bromo-2,3-dimethylnaphtho[2,3-*b*]thiophen-4-yl)-2,6-dimethylphenoxy]-3-phenylpropanoic acid

ertiprotafib

acide (2*R*)-2-[4-(9-bromo-2,3-diméthylnaphto[2,3-*b*]thiophén-4-yl)-2,6-diméthylphénoxy]-3-phénylpropanoïque

ertiprotafib

ácido (2*R*)-2-[4-(9-bromo-2,3-dimetilnafto[2,3-*b*]tiofen-4-il)-2,6-dimetilfenoxi]-3-fenilpropanoico $C_{31}H_{27}BrO_3S$ **eszopiclonum**


eszopiclone

(5*S*)-6-(5-chloropyridin-2-yl)-7-oxo-6,7-dihydro-5*H*-pyrrolo[3,4-*b*]pyrazin-5-yl-4-methylpiperazine-1-carboxylate

eszopiclone

4-méthylpipérazine-1-carboxylate de (5*S*)-6-(5-chloropyridin-2-yl)-7-oxo-6,7-dihydro-5*H*-pyrrolo[3,4-*b*]pyrazin-5-yle

eszopiclona

4-metilpiperazina-1-carboxilato de (5*S*)-6-(5-cloropiridin-2-il)-7-oxo-6,7-dihidro-5*H*-pirrolo[3,4-*b*]pirazin-5-ilo $C_{17}H_{17}ClN_6O_3$ 



**fandosentanum**


fandosentan

4-(7-ethyl-1,3-benzodioxol-5-yl)-2-[2-(trifluoromethyl)phenyl]-2*H*-1,2-benzothiazine-3-carboxylic acid 1,1-dioxide

fandosentan

1,1-dioxyde de l'acide 4-(7-éthyl-1,3-benzodioxol-5-yl)-2-[2-(trifluorométhyl)phényl]-2*H*-1,2-benzothiazine-3-carboxylique

fandosentán

1,1-dióxido del ácido 4-(7-etil-1,3-benzodioxol-5-il)-2-[2-(trifluorometil)fenil]-2*H*-1,2-benzotiazina-3-carboxílico $C_{25}H_{18}F_3NO_6S$ **fontolizumabum**

fontolizumab

immunoglobulin G1, anti-(human interferon  $\gamma$ ) (human-mouse monoclonal HuZAF  $\gamma$ 1-chain), disulfide with human-mouse monoclonal HuZAF light chain, dimer

fontolizumab

immunoglobuline G1, anti-(interféron  $\gamma$  humain) (chaîne  $\gamma$ 1 de l'anticorps monoclonal de souris HuZAF humanisé), dimère du disulfure avec la chaîne légère de l'anticorps monoclonal de souris HuZAF humanisé

fontolizumab

inmunoglobulina G1, anti-(interferón  $\gamma$  humano) (cadena  $\gamma$ 1 del anticuerpo monoclonal humanizado de ratón HuZAF), dímero del disulfuro con la cadena ligera del anticuerpo monoclonal humanizado de ratón HuZAF**garenoxacinum**


garenoxacin

1-cyclopropyl-8-(difluoromethoxy)-7-[(1*R*)-1-methyl-2,3-dihydro-1*H*-isoindol-5-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid

garénnoxacine

acide 1-cyclopropyl-8-(difluorométhoxy)-7-[(1*R*)-1-méthyl-2,3-dihydro-1*H*-isoindol-5-yl]-4-oxo-1,4-dihydroquinoléine-3-carboxylique

garenoxacina

ácido 1-ciclopropil-8-(difluorometoxi)-7-[(1*R*)-1-metil-2,3-dihidro-1*H*-isoindol-5-il]-4-oxo-1,4-dihidroquinolina-3-carboxílico $C_{23}H_{20}F_2N_2O_4$ 

**inecalcitolum**


inecalcitol

(7*E*)-19-nor-9,10-seco-14β-cholesta-5,7-dien-23-yne-1α,3β,25-triol

inécalcitol

(7*E*)-19-nor-9,10-séco-14β-cholesta-5,7-dién-23-yne-1α,3β,25-triol

inecalcitol

(7*E*)-19-nor-9,10-seco-14β-colesta-5,7-dien-23-ino-1α,3β,25-triol $C_{26}H_{40}O_3$ **iroxanadinum**


iroxanadine

(-)-5-(piperidin-1-ylmethyl)-3-(pyridin-3-yl)-5,6-dihydro-2*H*-1,2,4-oxadiazine

iroxanadine

(-)-5-(pipéridin-1-ylméthyl)-3-(pyridin-3-yl)-5,6-dihydro-2*H*-1,2,4-oxadiazine

iroxanadina

(-)-5-(piperidin-1-ilmetil)-3-(piridin-3-il)-5,6-dihidro-2*H*-1,2,4-oxadiazina $C_{14}H_{20}N_4O$ **lidorestatum**


lidorestat

[3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]-1*H*-indol-1-yl]acetic acid

lidorestat

acide [3-[(4,5,7-trifluorobenzothiazol-2-yl)méthyl]-1*H*-indol-1-yl]acétique

lidorestat

ácido [3-[(4,5,7-trifluorobenzotiazol-2-il)metil]-1*H*-indol-1-il]acético $C_{18}H_{11}F_3N_2O_2S$ 

**liraglutidum**



liraglutide

*N*<sup>26</sup>-(hexadecanoyl-γ-glutamyle)-[34-arginine]GLP-1-(7-37)-peptide

liraglutide

*N*<sup>26</sup>-(hexadécanoyl-γ-glutamyle)-[34-arginine]GLP-1-(7-37)-peptide

liraglutida

*N*<sup>26</sup>-(hexadecanoil-γ-glutamilo)-[34-arginina]GLP-1-(7-37)-péptido**lubiprostonum**



lubiprostone

(-)-7-[(2*R*,4*aR*,5*R*,7*aR*)-2-(1,1-difluoropentyl)-2-hydroxy-6-oxooctahydrocyclopenta[*b*]pyran-5-yl]heptanoic acid

lubiprostone

(-)-acide 7-[(2*R*,4*aR*,5*R*,7*aR*)-2-(1,1-difluoropentyl)-2-hydroxy-6-oxooctahydrocyclopenta[*b*]pyran-5-yl]heptanoïque

lubiprostona

(-)-ácido 7-[(2*R*,4*aR*,5*R*,7*aR*)-2-(1,1-difluoropentil)-2-hidroxi-6-oxooctahidrociclopenta[*b*]piran-5-il]heptanoico**lumiracoxibum**

lumiracoxib


[2-[(2-chloro-6-fluorophenyl)amino]-5-methylphenyl]acetic acid

lumiracoxib

acide [2-[(2-chloro-6-fluorophényl)amino]-5-méthylphényl]acétique

lumiracoxib

ácido [2-[(2-cloro-6-fluorofenil)amino]-5-metilfenil]acético

**merimepodibum**



merimepodib

(3*S*)-tetrahydrofuran-3-yl [3-[[[3-methoxy-4-(oxazol-5-yl)phenyl]carbamoyl]amino]benzyl]carbamate

mérimépodib

[3-[[[3-méthoxy-4-(oxazol-5-yl)phényl]carbamoyl]amino]benzyl]carbamate de (3*S*)-tétrahydrofuran-3-yle

merimepodib

[3-[[[3-metoxi-4-(oxazol-5-il)fenil]carbamoil]amino]bencil]carbamato de (3*S*)-tetrahidrofuran-3-ilo**mozavaptanum**



mozavaptan

*N*-[4-[[[(5*RS*)-5-(dimethylamino)-2,3,4,5-tetrahydro-1*H*-1-benzazepin-1-yl]carbonyl]phenyl]-2-methylbenzamide

mozavaptan

*N*-[4-[[[(5*RS*)-5-(diméthylamino)-2,3,4,5-tétrahydro-1*H*-1-benzazépin-1-yl]carbonyl]phényl]-2-méthylbenzamide

mozavaptán

*N*-[4-[[[(5*RS*)-5-(dimetilamino)-2,3,4,5-tetrahidro-1*H*-1-benzazepin-1-il]carbonil]fenil]-2-metilbenzamidaand enantiomer  
et énantiomère  
y enantiómero

**nalfurafinum**



nalfurafine

*(E)*-*N*-[17-(cyclopropylmethyl)-4,5 $\alpha$ -epoxy-3,14-dihydroxymorphinan-6 $\beta$ -yl]-3-(furan-3-yl)-*N*-methylprop-2-enamide

nalfurafine

*(E)*-*N*-[17-(cyclopropylméthyl)-4,5 $\alpha$ -époxy-3,14-dihydroxymorphinan-6 $\beta$ -yl]-3-(furan-3-yl)-*N*-méthylprop-2-énamide

nalfurafina

*(E)*-*N*-[17-(ciclopropilmetil)-4,5 $\alpha$ -epoxi-3,14-dihidroximorfinan-6 $\beta$ -il]-3-(furan-3-il)-*N*-metilprop-2-enamida**naminidilum**


naminidil

*N*-cyano-*N'*-(4-cyanophenyl)-*N''*-[(1*R*)-1,2,2-trimethylpropyl]guanidine

naminidil

*N*-cyano-*N'*-(4-cyanophényl)-*N''*-[(1*R*)-1,2,2-triméthylpropyl]guanidine

naminidil

*N*-ciano-*N'*-(4-cianofenil)-*N''*-[(1*R*)-1,2,2-trimetilpropil]guanidina**nemifitidum**

nemifitide



4-fluoro-L-phenylalanyl-*trans*-4-hydroxy-L-prolyl-L-arginylglycyl-L-tryptophanamide

némifitide

(4-fluoro-L-phénylalanil)-(*trans*-4-hydroxy-L-prolyl)-L-arginyl-glycyl-L-tryptophanamide

nemifitida

(4-fluoro-L-fenilalanil)-(*trans*-4-hidroxi-L-prolil)-L-arginilglicil-L-triptofanamida

**nortopixantronum**

nortopixantrone



2-[2-[(2-hydroxyethyl)amino]ethyl]-  
5-[[2-(methylamino)ethyl]amino]indazolo[4,3-*gh*]isoquinolin-6(2*H*)-one

nortopixantrone

2-[2-[(2-hydroxyéthyl)amino]éthyl]-  
5-[[2-(méthylamino)éthyl]amino]indazolo[4,3-*gh*]isoquinoléin-6(2*H*)-one

nortopixantrona

2-[2-[(2-hidroxietyl)amino]etil]-  
5-[[2-(metilamino)etil]amino]indazolo[4,3-*gh*]isoquinolin-6(2*H*)-ona



oblimeren

oblimeren

oblimerseno



$$\text{C}_{172} \text{H}_{221} \text{N}_{62} \text{O}_{91} \text{P}_{17} \text{S}_{17}$$

ortataxel

ortataxel

ortataxel

129

**osemozotanum**



osemozotan

3-(1,3-benzodioxol-5-yloxy)-*N*-[[(2*S*)-2,3-dihydro-1,4-benzodioxin-2-yl]methyl]propan-1-amine

osémozotan

3-(1,3-benzodioxol-5-yloxy)-*N*-[[(2*S*)-2,3-dihydro-1,4-benzodioxin-2-yl]méthyl]propan-1-amine

osemozotán

3-(1,3-benzodioxol-5-iloxi)-*N*-[[(2*S*)-2,3-dihidro-1,4-benzodioxin-2-il]metil]propan-1-amina**pascolizumabum**

pascolizumab

immunoglobulin G1, anti-(human interleukin 4) (human-mouse monoclonal SB-240683  $\gamma$ 1-chain), disulfide with human-mouse monoclonal SB-240683  $\kappa$ -chain, dimer

pascolizumab

immunoglobuline G1, anti-(interleukine 4 humaine) (chaîne  $\gamma$ 1 de l'anticorps monoclonal de souris SB-240683 humanisé), dimère du disulfure avec la chaîne  $\kappa$  de l'anticorps monoclonal de souris SB-240683 humanisé

pascolizumab

inmunoglobulina G1, anti-(interleukina 4 humana) (cadena  $\gamma$ 1 del anticuerpo monoclonal humanizado de ratón SB-240683), dímero del disulfuro con la cadena  $\kappa$  del anticuerpo monoclonal humanizado de ratón SB-240683



**pegaptanibum**

pegaptanib

5'-ester of (2'-deoxy-2'-fluoro)C-Gm-Gm-A-A-(2'-deoxy-2'-fluoro)U-(2'-deoxy-2'-fluoro)C-Am-Gm-(2'-deoxy-2'-fluoro)U-Gm-Am-Am-(2'-deoxy-2'-fluoro)U-Gm-(2'-deoxy-2'-fluoro)C-(2'-deoxy-2'-fluoro)U-(2'-deoxy-2'-fluoro)U-Am-(2'-deoxy-2'-fluoro)U-Am-(2'-deoxy-2'-fluoro)C-Am-(2'-deoxy-2'-fluoro)U-(2'-deoxy-2'-fluoro)C-(2'-deoxy-2'-fluoro)C-Gm-(3'→3')-dT with  $\alpha, \alpha'$ -[[[(1S)-1-[[5-(phosphonoxy)pentyl]carbamoyl]pentane-1,5-diyl]bis(iminocarbonyl)]bis[ $\omega$ -methoxypoly(oxyethane-1,2-diyl)]]

pégaptanib


(2'-désoxy-2'-fluoro)C-Gm-Gm-A-A-(2'-désoxy-2'-fluoro)U-(2'-désoxy-2'-fluoro)C-Am-Gm-(2'-désoxy-2'-fluoro)U-Gm-Am-Am-(2'-désoxy-2'-fluoro)U-Gm-(2'-désoxy-2'-fluoro)C-(2'-désoxy-2'-fluoro)U-(2'-désoxy-2'-fluoro)U-Am-(2'-désoxy-2'-fluoro)U-Am-(2'-désoxy-2'-fluoro)C-Am-(2'-désoxy-2'-fluoro)U-(2'-désoxy-2'-fluoro)C-(2'-désoxy-2'-fluoro)C-Gm-(3'→3')-dT 5'-estérifié par  $\alpha, \alpha'$ -[[[(1S)-1-[[5-(phosphonoxy)pentyl]carbamoyl]pentane-1,5-diyl]bis(iminocarbonyl)]bis[ $\omega$ -méthoxypoly(oxyéthane-1,2-diyl)]]

pegaptanib

(2'-desoxi-2'-fluoro)C-Gm-Gm-A-A-(2'-desoxi-2'-fluoro)U-(2'-desoxi-2'-fluoro)C-Am-Gm-(2'-desoxi-2'-fluoro)U-Gm-Am-Am-(2'-desoxi-2'-fluoro)U-Gm-(2'-desoxi-2'-fluoro)C-(2'-desoxi-2'-fluoro)U-(2'-desoxi-2'-fluoro)U-Am-(2'-desoxi-2'-fluoro)U-Am-(2'-desoxi-2'-fluoro)C-Am-(2'-desoxi-2'-fluoro)U-(2'-desoxi-2'-fluoro)C-(2'-desoxi-2'-fluoro)C-Gm-(3'→3')-dT 5'-esterificado con  $\alpha, \alpha'$ -[[[(1S)-1-[[5-(fosfonoxy)pentil]carbamoyl]pentano-1,5-diil]bis(iminocarbonil)]bis[ $\omega$ -metoxipoli(oxiétano-1,2-diilo)]]



$$x + y = n$$

**pegsunerceptum**

pegsunercept


pegylated L-methionyl-1-105-human tumor necrosis factor receptor p55

pegsunercept

L-méthionyl-1-105-récepteur p55 du facteur de nécrose tumorale humain, pegylé

pegsunercept

L-metionil-1-105-receptor p55 del factor de necrosis tumoral humano, pegilado

**perflubrodecum**

perflubrodec


1-bromohenicosafuorodecane

perflubrodec

1-bromohénicosafuorodécane

perflubrodec

1-bromohenicosafuorodecano

**picoplatinum**

picoplatin



(SP-4-3)-amminedichloro(2-methylpyridine)platinum

picoplatine

(SP-4-3)-amminedichloro(2-méthylpyridine)platine

picoplatino

(SP-4-3)-aminodicloro(2-metilpiridina)platino



DSVCPQGY

CRECESGSF

RDTVCGCRK

**plevitrexedum**


plevitrexed

(2*S*)-2-[[4-[[[(2,7-dimethyl-4-oxo-1,4-dihydroquinazolin-6-yl)methyl](prop-2-ynyl)amino]-2-fluorobenzoyl]amino]-4-(1*H*-tetrazol-5-yl)butanoic acid

plévitrexed

acide (2*S*)-2-[[4-[[[(2,7-diméthyl-4-oxo-1,4-dihydroquinazolin-6-yl)méthyl](prop-2-ynyl)amino]-2-fluorobenzoyl]amino]-4-(1*H*-tétrazol-5-yl)butanoïque

plevitrexed

ácido (2*S*)-2-[[4-[[[(2,7-dimetil-4-oxo-1,4-dihidroquinazolin-6-il)metil](prop-2-inil)amino]-2-fluorobenzoil]amino]-4-(1*H*-tetrazol-5-il)butanoico $C_{26}H_{25}FN_8O_4$ **pumosetragum**


pumosetrag

*N*-[(3*R*)-1-azabicyclo[2.2.2]oct-3-yl]-7-oxo-4,7-dihydrothieno[3,2-*b*]pyridine-6-carboxamide

pumosétrag

*N*-[(3*R*)-1-azabicyclo[2.2.2]oct-3-yl]-7-oxo-4,7-dihydrothiéno[3,2-*b*]pyridine-6-carboxamide

pumosetrag

*N*-[(3*R*)-1-azabicyclo[2.2.2]oct-3-il]-7-oxo-4,7-dihidrotieno[3,2-*b*]piridina-6-carboxamida $C_{15}H_{17}N_3O_2S$ **siplizumabum**

siplizumab

immunoglobulin G1, anti-(human CD2 (antigen)) (human-rat monoclonal MEDI-507  $\gamma$ 1-chain), disulfide with human-rat monoclonal MEDI-507 light chain, dimer

siplizumab

immunoglobuline G1, anti-(antigène humain CD2) (chaîne  $\gamma$ 1 de l'anticorps monoclonal de rat MEDI-507 humanisé), dimère du disulfure avec la chaîne légère de l'anticorps monoclonal de rat MEDI-507 humanisé

siplizumab

inmunoglobulina G1, anti-(antígeno humano CD2) (cadena  $\gamma$ 1 del anticuerpo monoclonal de rata humanizado MEDI-507), dímero del disulfuro con la cadena ligera del anticuerpo monoclonal de rata humanizado MEDI-507

**soraprazanum**


soraprazan

(7*R*,8*R*,9*R*)-7-(2-methoxyethoxy)-2,3-dimethyl-9-phenyl-7,8,9,10-tetrahydroimidazo[1,2-*h*][1,7]naphthyridin-8-ol

soraprazan

(7*R*,8*R*,9*R*)-7-(2-méthoxyéthoxy)-2,3-diméthyl-9-phényl-7,8,9,10-tétrahydroimidazo[1,2-*h*][1,7]naphtyridin-8-ol

soraprazán

(7*R*,8*R*,9*R*)-9-fenil-2,3-dimetil-7-(2-metoxietoxi)-7,8,9,10-tetrahydroimidazo[1,2-*h*][1,7]naftiridin-8-ol $C_{21}H_{25}N_3O_3$ **tapentadolum**


tapentadol

3-[(1*R*,2*R*)-3-(dimethylamino)-1-ethyl-2-methylpropyl]phenol

tapentadol

3-[(1*R*,2*R*)-3-(diméthylamino)-1-éthyl-2-méthylpropyl]phénol

tapentadol

3-[(1*R*,2*R*)-3-(dimetilamino)-1-etil-2-metilpropil]fenol $C_{14}H_{23}NO$ **tecadenosonum**

tecadenoson



9-β-D-ribofuranosyl-*N*-[(3*R*)-tetrahydrofuran-3-yl]-9*H*-purin-6-amine

técadénoson

9-β-D-ribofuranosyl-*N*-[(3*R*)-tétrahydrofuran-3-yl]-9*H*-purin-6-amine

tecadenosón

9-β-D-ribofuranosil-*N*-[(3*R*)-tetrahydrofuran-3-il]-9*H*-purin-6-amina

**tecalcetum**



tecalcet

3-(2-chlorophenyl)-*N*-[(1*R*)-1-(3-methoxyphenyl)ethyl]propan-1-amine

técalcet

3-(2-chlorophényl)-*N*-[(1*R*)-1-(3-méthoxyphényl)éthyl]propan-1-amine

tecalcet

3-(2-clorofenil)-*N*-[(1*R*)-1-(3-metoxifenil)etil]propan-1-amina**teneliximabum**

teneliximab

immunoglobulin G1, anti-(human CD40 (antigen)) (human-mouse monoclonal chi220  $\gamma$ 1-chain), disulfide with human-mouse monoclonal chi220 light chain, dimer

ténéliximab

immunoglobuline G1, anti-(antigène CD40 humain) (chaîne  $\gamma$ 1 de l'anticorps monoclonal chimérique homme souris chi220), dimère du disulfure avec la chaîne légère de l'anticorps monoclonal chimérique homme souris chi220

teneliximab

inmunoglobulina G1, anti-(antígeno CD40 humano) (cadena  $\gamma$ 1 del anticuerpo monoclonal quimérico hombre ratón chi220), dímero del disulfuro con la cadena ligera del anticuerpo monoclonal quimérico hombre ratón chi220

**topixantronum**


topixantrone

5-[[2-(dimethylamino)ethyl]amino]-  
2-[2-[(2-hydroxyethyl)amino]ethyl]indazolo[4,3-*gh*]isoquinolin-6(2*H*)-one

topixantrone

5-[[2-(diméthylamino)éthyl]amino]-  
2-[2-[(2-hydroxyéthyl)amino]éthyl]indazolo[4,3-*gh*]isoquinoléin-6(2*H*)-one

topixantrona

5-[[2-(dimetilamino)etil]amino]-  
2-[2-[(2-hidroxietil)amino]etil]indazolo[4,3-*gh*]isoquinolin-6(2*H*)-ona $C_{21}H_{26}N_6O_2$ **toralizumabum**

toralizumab

immunoglobulin G1, anti-(human CD40 ligand) (human-mouse monoclonal IDEC-131  $\gamma$ 1-chain), disulfide with human-mouse monoclonal IDEC-131  $\kappa$ -chain, dimer

toralizumab

immunoglobuline G1, anti-(ligand CD40 humain) (chaîne  $\gamma$ 1 de l'anticorps monoclonal de souris IDEC-131 humanisé), dimère du disulfure avec la chaîne  $\kappa$  de l'anticorps monoclonal de souris IDEC-131 humanisé

toralizumab

inmunoglobulina G1, anti-(ligando CD40 humano) (cadena  $\gamma$ 1 del anticuerpo monoclonal humanizado de ratón IDEC-131), dímero del disulfuro con la cadena  $\kappa$  del anticuerpo monoclonal humanizado de ratón IDEC-131**torcetrapibum**


torcetrapib

ethyl (2*R*,4*S*)-4-[[3,5-bis(trifluoromethyl)benzyl](methoxycarbonyl)amino]-2-ethyl-6-(trifluoromethyl)-3,4-dihydroquinoline-1(2*H*)-carboxylate

torcétrapib


(2*R*,4*S*)-4-[[[3,5-bis(trifluorométhyl)benzyl](méthoxycarbonyl)amino]-2-éthyl-6-(trifluorométhyl)-3,4-dihydroquinoléine-1(2*H*)-carboxylate d'éthyle

torcetrapib


(2*R*,4*S*)-4-[[[3,5-bis(trifluorometil)bencil](metoxicarbonil)amino]-2-etil-6-(trifluorometil)-3,4-dihidroquinolina-1(2*H*)-carboxilato de etilo $C_{26}H_{25}F_9N_2O_4$ 

**torcitabinum**


torcitabine	4-amino-1-(2-deoxy-β-L- <i>erythro</i> -pentofuranosyl)pyrimidin-2(1 <i>H</i> )-one
torcitabine	4-amino-1-(2-désoxy-β-L- <i>érythro</i> -pentofuranosyl)pyrimidin-2(1 <i>H</i> )-one
torcitabina	4-amino-1-(2-desoxi-β-L- <i>eritro</i> -pentofuranosil)pirimidin-2(1 <i>H</i> )-ona
	$C_9H_{13}N_3O_4$

**treprostinilum**

treprostinil	[[[(1 <i>R</i> ,2 <i>R</i> ,3 <i>aS</i> ,9 <i>aS</i> )-2-hydroxy-1-[(3 <i>S</i> )-3-hydroxyoctyl]-2,3,3 <i>a</i> ,4,9,9 <i>a</i> -hexahydro-1 <i>H</i> -cyclopenta[ <i>b</i> ]naphthalen-5-yl]oxy]acetic acid
tréprostinil	acide [[[(1 <i>R</i> ,2 <i>R</i> ,3 <i>aS</i> ,9 <i>aS</i> )-2-hydroxy-1-[(3 <i>S</i> )-3-hydroxyoctyl]-2,3,3 <i>a</i> ,4,9,9 <i>a</i> -hexahydro-1 <i>H</i> -cyclopenta[ <i>b</i> ]naphthalén-5-yl]oxy]acétique
treprostinilo	ácido [[[(1 <i>R</i> ,2 <i>R</i> ,3 <i>aS</i> ,9 <i>aS</i> )-2-hidroxi-1-[(3 <i>S</i> )-3-hidroxiocetil]-2,3,3 <i>a</i> ,4,9,9 <i>a</i> -hexahidro-1 <i>H</i> -ciclopenta[ <i>b</i> ]naftalen-5-il]oxi]acético

**triplatinum tetranitras**

triplatin tetranitrate	<i>trans</i> -[bis[ <i>trans</i> -diamminechloroplatinium(μ-hexane-1,6-diamine)]]diammineplatinum tetranitrate
tétranitrate de triplatine	tétranitrate de <i>trans</i> -[bis[ <i>trans</i> -diamminechloroplatine(μ-hexane-1,6-diamine)]]diammineplatine
tetranitrato de triplatino	tetranitrato de <i>trans</i> -[bis[ <i>trans</i> -diaminacloroplatino(μ-hexano-1,6-diamina)]]diaminaplatino



**tulathromycinum**  
tulathromycin

Mixture of two compounds (in equilibrium in solution):

tulathromycinum A

(2*R*,3*S*,4*R*,5*R*,8*R*,10*R*,11*R*,12*S*,13*S*,14*R*)-13-[(2,6-dideoxy-3-*C*-methyl-3-*O*-methyl-4-*C*-[(propylamino)methyl]- $\alpha$ -*L*-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,8,10,12,14-hexamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)- $\beta$ -*D*-xylo-hexopyranosyl]oxy]-1-oxa-6-azacyclopentadecan-15-one

tulathromycinum B

(2*R*,3*R*,6*R*,8*R*,9*R*,10*S*,11*S*,12*R*)-11-[(2,6-dideoxy-3-*C*-methyl-3-*O*-methyl-4-*C*-[(propylamino)methyl]- $\alpha$ -*L*-ribo-hexopyranosyl)oxy]-2-[(1*R*,2*R*)-1,2-dihydroxy-1-methylbutyl]-8-hydroxy-3,6,8,10,12-pentamethyl-9-[[3,4,6-trideoxy-3-(dimethylamino)- $\beta$ -*D*-xylo-hexopyranosyl]oxy]-1-oxa-4-azacyclotridecan-13-one

tulathromycine

Mélange de deux composés (en équilibre en solution):

tulathromycinum A

(2*R*,3*S*,4*R*,5*R*,8*R*,10*R*,11*R*,12*S*,13*S*,14*R*)-13-[(2,6-didésoxy-3-*C*-méthyl-3-*O*-méthyl-4-*C*-[(propylamino)méthyl]- $\alpha$ -*L*-ribo-hexopyranosyl)oxy]-2-éthyl-3,4,10-trihydroxy-3,5,8,10,12,14-hexaméthyl-11-[[3,4,6-tridésoxy-3-(diméthylamino)- $\beta$ -*D*-xylo-hexopyranosyl]oxy]-1-oxa-6-azacyclopentadécan-15-one

tulathromycinum B

(2*R*,3*R*,6*R*,8*R*,9*R*,10*S*,11*S*,12*R*)-11-[(2,6-didésoxy-3-*C*-méthyl-3-*O*-méthyl-4-*C*-[(propylamino)méthyl]- $\alpha$ -*L*-ribo-hexopyranosyl)oxy]-2-[(1*R*,2*R*)-1,2-dihydroxy-1-méthylbutyl]-8-hydroxy-3,6,8,10,12-pentaméthyl-9-[[3,4,6-tridésoxy-3-(diméthylamino)- $\beta$ -*D*-xylo-hexopyranosyl]oxy]-1-oxa-4-azacyclotridécan-13-one

tulatromicina

Mezcla de dos componentes (en equilibrio en solución):

tulathromycinum A



(2*R*,3*S*,4*R*,5*R*,8*R*,10*R*,11*R*,12*S*,13*S*,14*R*)-13-[(2,6-didesoxi-3-*C*-metil-3-*O*-metil-4-*C*-[(propilamino)metil]- $\alpha$ -*L*-ribo-hexopiranosil)oxi]-2-etil-3,4,10-trihidroxi-3,5,8,10,12,14-hexametil-11-[[3,4,6-tridesoxi-3-(dimetilamino)- $\beta$ -*D*-xilo-hexopiranosil]oxi]-1-oxa-6-azaciclopentadecan-15-ona

tulathromycinum B

(2*R*,3*R*,6*R*,8*R*,9*R*,10*S*,11*S*,12*R*)-11-[(2,6-didesoxi-3-*C*-metil-3-*O*-metil-4-*C*-[(propilamino)metil]- $\alpha$ -*L*-ribo-hexopiranosil)oxi]-2-[(1*R*,2*R*)-1,2-dihidroxi-1-metilbutil]-8-hidroxi-3,6,8,10,12-pentametil-9-[[3,4,6-tridesoxi-3-(dimetilamino)- $\beta$ -*D*-xilo-hexopiranosil]oxi]-1-oxa-4-azaciclotridecan-13-ona



$C_{41}H_{79}N_3O_{12}$  tulathromycin A  
 $C_{41}H_{79}N_3O_{12}$  tulathromycin B



**vapaliximabum**  
vapaliximab

immunoglobulin G2, anti-(human vascular adhesion protein VAP-1) (human-mouse monoclonal 2D10  $\gamma$ 2-chain), disulfide with human-mouse monoclonal 2D10  $\kappa$ -chain, dimer

vapaliximab

immunoglobuline G2, anti-(protéine d'adhésion vasculaire humaine VAP-1) (chaîne  $\gamma$ 2 de l'anticorps monoclonal chimérique homme-souris 2D10), dimère du disulfure avec la chaîne  $\kappa$  de l'anticorps monoclonal chimérique homme-souris 2D10

vapaliximab

inmunoglobulina G2, anti-(proteína de adhesión vascular humana VAP-1) (cadena  $\gamma$ 2 del anticuerpo monoclonal quimérico hombre-ratón 2D10), dímero del disulfuro con la cadena  $\kappa$  del anticuerpo monoclonal quimérico hombre-ratón 2D10

**varespladibum**


varespladib

[[3-(aminooxoacetyl)-1-benzyl-2-ethyl-1*H*-indol-4-yl]oxy]acetic acid

varespladib

acide [[3-(aminooxoacétyl)-1-benzyl-2-éthyl-1*H*-indol-4-yl]oxy]acétique

varespladib

ácido [[3-(aminooxoacetil)-1-bencil-2-etil-1*H*-indol-4-il]oxi]acético $C_{21}H_{20}N_2O_5$ 

---

**AMENDMENTS TO PREVIOUS LISTS  
MODIFICATIONS APPORTÉES AUX LISTES ANTÉRIEURES  
MODIFICACIONES A LAS LISTAS ANTERIORES**

**Recommended International Nonproprietary Names (Rec. INN): List 46**  
**Dénominations communes internationales recommandées (DCI Rec.): Liste 46**  
**Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 46**  
*(WHO Drug Information, Vol. 15, No. 3-4, 2001)*

- |   |   |
|---|---|
| p. 208 <b>reglitazarum</b><br>reglitazar                  | <i>sustituyase la descripción por la siguiente:</i><br>(4 <i>RS</i> )-4-[4-[2-fenil-5-metiloxazol-4-il)etoxi]bencil]isoxazolidina-3,5-diona                     |
| p. 208 <b>rivoglitazonum</b><br>rivoglitazona             | <i>sustituyase la descripción por la siguiente:</i><br>(5 <i>RS</i> )-5-[4-[(1-metil-6-metoxi-1 <i>H</i> -bencimidazol-2-il)metoxi]bencil]tiazolidina-2,4-diona |
| p. 217 <i>delete/supprimer/suprimase</i>                  | <i>insert/insérer/insértase</i>   |
| <b>tebipenemum</b><br>tebipenem<br>tébipénem<br>tebipenem | <b>tebipenemum pivoxilum</b><br>tebipenem pivoxil<br>tébipénem pivoxil<br>tebipenem pivoxilo  |

**Recommended International Nonproprietary Names (Rec. INN): List 48**  
**Dénominations communes internationales recommandées (DCI Rec.): Liste 48**  
**Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 48**  
*(WHO Drug Information, Vol. 16, No. 3, 2002)*

- |  |  |
|--|--|
| p. 255 <b>metelimumabum</b><br>metelimumab | <i>replace the description by the following:</i><br>immunoglobulin G4, anti-(human transforming growth factor $\beta$ 1)<br>(human monoclonal CAT-192 $\gamma$ 4-chain), disulfide with human<br>monoclonal CAT-192 $\kappa$ -chain, dimer |
|--|--|

p. 258 **paliferminum**

palifermin

*replace the description and the graphic formula by the following:*  
human fibroblast growth factor-(24-163)-peptide

palifermine

*remplacer la description et la formule développée par la suivante:*  
peptide-(24-163)-facteur de croissance du fibroblaste humain

palifermina

*sustitúyase la descripción y la fórmula empírica por la siguiente:*  
péptido-(24-163)-factor de crecimiento del fibroblasto humano

			SYDYMEG	GDIRVRRRFC
RTQWYLRIK	RGKVKGTE	KNNYNIMEIR	TVAVGIVAIAK	
GVESEFYLAM	NKEGKLYAKK	ECNEDCNFKE	LILENHYNTRY	
ASAKWTHNGG	EMFVALNQKG	IPVRGKKTKK	EQKTAHFLPM	
AIT				

p. 267 *delete/supprimer/suprimase**insert/insérer/insértase*

pitrakinraum

pitrakinrum

**Procedure and Guiding Principles / Procédure et Directives / Procedimientos y principios generales**

The text of the *Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances* and *General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical Substances* will be reproduced in uneven numbers of proposed INN lists only.

Les textes de la *Procédure à suivre en vue du choix de dénominations communes internationales recommandées pour les substances pharmaceutiques* et des *Directives générales pour la formation de dénominations communes internationales applicables aux substances pharmaceutiques* seront publiés seulement dans les numéros impaires des listes des DCI proposées.

El texto de los *Procedimientos de selección de denominaciones comunes internacionales recomendadas para las sustancias farmacéuticas* y de los *Principios generales de orientación para formar denominaciones comunes internacionales para sustancias farmacéuticas* aparece solamente en los números impares de las listas de DCI propuestas.